A Study of Revumenib and Mezigdomide in People With Leukemia

This study is testing a combination of two drugs — revumenib (a menin inhibitor that targets certain leukemia-driving gene mutations) and mezigdomide (an immune-modulating drug) — for people with relapsed or treatment-resistant acute leukemia. The study includes both adults and children aged 12 and older whose leukemia has specific genetic mutations (NPM1, KMT2A, or NUP98). **You may be eligible if:** - You are 12 years or older and weigh at least 40 kg - You have been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia that has relapsed or not responded to at least one prior treatment - Your leukemia has a specific genetic mutation: NPM1, KMT2A translocation, or NUP98 translocation - Your general health status is adequate based on age-appropriate performance scales - Your heart, liver, and kidney function are within acceptable ranges **You may NOT be eligible if:** - You have acute promyelocytic leukemia (APL) or isolated myeloid sarcoma - You have previously been treated with mezigdomide - You have a life-threatening leukemia complication such as uncontrolled bleeding or severe infection - You have another cancer that would make results harder to interpret - You have active graft-versus-host disease (GVHD) of grade 2 or higher requiring treatment - You have active HIV, hepatitis B, or hepatitis C infection - You have had a serious heart event in the past 6 months Talk to your doctor to see if this trial is right for you.